

EQA round: AIM11/25 - Autoimmunity 1

Deadline: 14.3.2025

Setup: groups - M (measurement principle)

AV = assigned value	N _{tot} = total number of the results	N _{eva} = number of the results assessed
CVP = consensus of all participants	N _{rel} = relative number of the results	N _{suc} = number of successful results
>>> ... expected result		S _{rel} = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
Set 1								
(560) ANA screening (antibodies against cell nucleus) - prove		81			81	81	100	
Sample A1		81			81	81	100	
(1) Fluorescent methods	CVP >>>	74	91	Positive				
(2) EIA methods	CVP >>>	6	7,4	Positive				
(99) Another measurement principle	CVP >>>	1	1,2	Positive				
Sample B1		81			81	81	100	
(1) Fluorescent methods	CVP >>>	74	91	Negative				
(2) EIA methods	CVP >>>	6	7,4	Negative				
(99) Another measurement principle	CVP >>>	1	1,2	Negative				
(572) ANA screening (antibodies against cell nucleus) - semi-quantity		71			0			
Sample A1		71			0			
(0) Not specified	±	2	2,8	titre 40				
	±	2	2,8	titre 80				
	±	2	2,8	titre 160				
	±	26	37	titre 320				
	±	23	32	titre 640				
	±	12	17	titre 1280				
	±	4	5,6	titre 2560				
Sample B1		71			0			
(0) Not specified	±	1	1,4	Not specified				
	±	56	79	titre 0 (not measurable)				
	±	5	7	titre 40				
	±	8	11	titre 80				
	±	1	1,4	titre 2560				
(561) ANA - type of fluorescence - nucleus		74			74	70	95	
Sample A1		74			74	73	99	
(0) Not specified	CVP >>>	73	99	Fine or coarse speckled or nuclear matrix (AC-4/AC-5)				
		1	1,4	Fine or coarse speckled or nuclear matrix (AC-4/AC-5); DFS 70 (AC-2)				
Sample B1		74			74	71	96	
(0) Not specified		3	4,1	Not specified				
	CVP >>>	71	96	No fluorescence (AC-0)				
(563) ANA screening (antibodies against cytoplasm) - prove		72			72	71	99	
Sample A1		72			72	71	99	
(1) Fluorescent methods	CVP >>>	71	99	Negative				
		1	1,4	Positive				
Sample B1		72			72	72	100	
(1) Fluorescent methods	CVP >>>	72	100	Negative				
(573) ANA screening (antibodies against cytoplasm) - semi-quantity		68			0			
Sample A1		68			0			
(0) Not specified	±	53	78	titre 0 (not measurable)				
	±	5	7,4	titre 40				
	±	8	12	titre 80				
	±	1	1,5	titre 640				
	±	1	1,5	titre 2560				
Sample B1		68			0			
(0) Not specified	±	54	79	titre 0 (not measurable)				
	±	5	7,4	titre 40				
	±	8	12	titre 80				
	±	1	1,5	titre 2560				
(564) ANA - type of fluorescence - cytoplasm		69			69	68	99	
Sample A1		69			69	68	99	
(0) Not specified	CVP >>>	68	99	No fluorescence (AC-0)				
		1	1,4	Dense or fine speckled cytoplasm (AC-19/AC-20)				
Sample B1		69			69	69	100	
(0) Not specified	CVP >>>	69	100	No fluorescence (AC-0)				

EQA round: AIM11/25 - Autoimmunity 1

Deadline: 14.3.2025

Setup: groups - M (measurement principle)

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
Set 2							
(585) anti-centromere		75			75	75	100
Sample A2		75			75	75	100
(1) Fluorescent methods	CVP >>>	9	12	Negative			
(2) EIA methods	CVP >>>	19	25	Negative			
(5) LIA, ILMA	CVP >>>	4	5,3	Negative			
(6) Immunoblotting	CVP >>>	43	57	Negative			
Sample B2		75			75	75	100
(1) Fluorescent methods	CVP >>>	9	12	Negative			
(2) EIA methods	CVP >>>	19	25	Negative			
(5) LIA, ILMA	CVP >>>	4	5,3	Negative			
(6) Immunoblotting	CVP >>>	43	57	Negative			
(584) anti-ENA, antigen Jo-1		78			78	77	99
Sample A2		78			78	77	99
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	29	37	Negative			
(5) LIA, ILMA	CVP >>>	4	5,1	Negative			
(6) Immunoblotting	CVP >>>	43	55	Negative			
		1	1,3	Inconclusive result (borderline)			
Sample B2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	29	37	Negative			
(5) LIA, ILMA	CVP >>>	5	6,4	Negative			
(6) Immunoblotting	CVP >>>	43	55	Negative			
(583) anti-ENA, antigen RNP		78			78	67	86
Sample A2		78			78	68	87
(1) Fluorescent methods	CVP >>>	1	1,3	Positive			
(2) EIA methods	CVP >>>	5	6,4	Negative			
	CVP >>>	22	28	Positive			
(5) LIA, ILMA	CVP >>>	5	6,4	Positive			
(6) Immunoblotting	CVP >>>	4	5,1	Negative			
	CVP >>>	1	1,3	Inconclusive result (borderline)			
Sample B2		40	51	Positive			
Sample B2		78			78	77	99
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	27	35	Negative			
(5) LIA, ILMA	CVP >>>	5	6,4	Negative			
(6) Immunoblotting	CVP >>>	44	56	Negative			
		1	1,3	Positive			
(582) anti-ENA, antigen Scl-70		78			78	78	100
Sample A2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	28	36	Negative			
(5) LIA, ILMA	CVP >>>	5	6,4	Negative			
(6) Immunoblotting	CVP >>>	44	56	Negative			
Sample B2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	28	36	Negative			
(5) LIA, ILMA	CVP >>>	5	6,4	Negative			
(6) Immunoblotting	CVP >>>	44	56	Negative			
(580) anti-ENA, antigen SS-A/Ro-60		78			78	78	100
Sample A2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Positive			
(2) EIA methods	CVP >>>	28	36	Positive			
(5) LIA, ILMA	CVP >>>	5	6,4	Positive			
(6) Immunoblotting	CVP >>>	44	56	Positive			
Sample B2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	28	36	Negative			
(5) LIA, ILMA	CVP >>>	5	6,4	Negative			
(6) Immunoblotting	CVP >>>	44	56	Negative			
(581) anti-ENA, antigen SS-B/La		78			78	78	100
Sample A2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Positive			
(2) EIA methods	CVP >>>	28	36	Positive			
(5) LIA, ILMA	CVP >>>	5	6,4	Positive			
(6) Immunoblotting	CVP >>>	44	56	Positive			

EQA round: AIM11/25 - Autoimmunity 1

Deadline: 14.3.2025

Setup: groups - M (measurement principle)

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
Sample B2		78			78	78	100
(1) Fluorescent methods	CVP >>>	1	1,3	Negative			
(2) EIA methods	CVP >>>	28	36	Negative			
(5) LIA, ILMA	CVP >>>	5	6,4	Negative			
(6) Immunoblotting	CVP >>>	44	56	Negative			
Set 3							
(588) anti-dsDNA immunofluorescence - prove		56			56	54	96
Sample A3		56			56	55	98
(0) Not specified	CVP >>>	55	98	Negative			
		1	1,8	Positive			
Sample B3		56			56	54	96
(0) Not specified		2	3,6	Negative			
	CVP >>>	54	96	Positive			
(577) anti-dsDNA immunofluorescence - semi-quantity		52			0		
Sample A3		52			0		
(0) Not specified	±	1	1,9	Not specified			
	±	44	85	titre 0 (not measurable)			
	±	6	12	titre 10			
	±	1	1,9	titre 2560			
Sample B3		52			0		
(0) Not specified	±	2	3,8	titre 10			
	±	3	5,8	titre 20			
	±	2	3,8	titre 40			
	±	16	31	titre 80			
	±	11	21	titre 160			
	±	13	25	titre 320			
	±	4	7,7	titre 640			
	±	1	1,9	titre 2560			
(589) anti-dsDNA other methods		61			61	56	92
Sample A3		61			61	58	95
(2) EIA methods	CVP >>>	43	70	Negative			
(5) LIA, ILMA	CVP >>>	6	9,8	Negative			
		2	3,3	Inconclusive result (borderline)			
		1	1,6	Positive			
(6) Immunoblotting	CVP >>>	8	13	Negative			
(99) Another measurement principle	CVP >>>	1	1,6	Negative			
Sample B3		61			61	59	97
(2) EIA methods	CVP >>>	43	70	Positive			
(5) LIA, ILMA	CVP >>>	9	15	Positive			
(6) Immunoblotting		2	3,3	Negative			
	CVP >>>	6	9,8	Positive			
(99) Another measurement principle	CVP >>>	1	1,6	Positive			
Set 4							
(591) anti-nukleosomes IgG		55			55	55	100
Sample A4		55			55	55	100
(2) EIA methods	CVP >>>	36	65	Negative			
(6) Immunoblotting	CVP >>>	19	35	Negative			
Sample B4		55			55	55	100
(2) EIA methods	CVP >>>	36	65	Positive			
(6) Immunoblotting	CVP >>>	19	35	Positive			